AGILeBiotics B.V. is an early-stage pharmaceutical company focusing on the development of novel antibiotics. We are passionately translating innovation into novel antibacterials to treat patients infected by life-threatening hospital-acquired multidrug-resistant infections.
Founded in 2017 as a spin-off company of the University of Groningen, AGILeBiotics is using a proprietary technology for the development of novel and safe treatment options for hospitalised patients in intensive care units suffering from multidrug-resistant Gram-negative infections.
Pharma Connect Capital B.V.
Carduso Capital B.V.
Stichting i.r. G.J. Smid Fonds B.V.
Rug Houdstermaatschappij B.V.
AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.
Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.
Santo Holding (Deutschland) GmbH and other private investors
AIC499 - a Superior Gram-negative Resistance Breaker
Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company. Through its Swiss subsidiary Basilea Pharmaceutica International Ltd. the company is developing products that address the medical challenge of increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
Listed on the SIX Swiss Exchange (SIX: BSLN)
Acute bacterial skin and skin structure infections, Staphylococcus aureus bacteremia
Community- and hospital-acquired pneumonia (excluding ventilator-associated pneumonia)
Combioxin SA develops innovative anti-virulence treatments for bacterial infections. CAL02 is a clinical-stage first-in-class drug that neutralizes deadly toxins produced by a large panel of bacteria, including multi-resistant strains. CAL02 aims at saving lives, protecting against long-term consequences from severe infections and fighting antibiotic resistance.
Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
Destiny Pharma anti-microbial drug productsDestiny Pharma’s Vision is of an expanding range of new antimicrobial drug products which operate within existing antibiotic markets but due to their unique features, open significant, new markets that are closed to traditional antibiotics due to the existence or threat of antibiotic resistance.
The proprietary, new antimicrobial drug platform at Destiny Pharma, the XF Drug Series, act via an ultra-rapid action which kill bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance response.
Motif Bio is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings. Motif is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram positive and Gram negative bacteria
Staphylococcus aureus Lung Infections Among Cystic Fibrosis Patients
Neem Biotech is a Wales-based R&D life sciences centre that brings with it significant expertise in the biology and chemistry of bioactive compounds, and transforms these into platform technology resources for application in the fight against global threats to human and animal health. This includes antimicrobial resistance. Particular areas of research interest include cystic fibrosis and controlling infection in the healing of chronic wounds. Neem is fully owned by the life-science group Zaluvida. Neem Biotech’s aim is to enhance the life expectancy of patients and the quality of life of both patients and their families.
PhagoMed accelerates the re-introduction of phage therapy. We are an experience team of microbiologists, physicians and business leaders with the common passion to develop medicines against bacterial infections.
Summit is a leader in antibiotic innovation. Its new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. Summit is currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and is using its proprietary Discuva Platform to expand its pipeline. Summit is headquartered in the UK with offices in Oxford and Cambridge, and has an office in Cambridge, US. Summit is a public company with listing on NASDAQ (SMMT) and LSE (SUMM).
Vaxdyn is a start-up company dedicated to drug development. The aim of Vaxdyn is to develop drug candidates for immunotherapy against untreatable or difficult-to-treat infections, both hospital-acquired infections and community acquired infections.
Monoclonal antibodies against hospital-acquired infections and community acquired infections caused by Acinetobacter baumannii
Vaccine against hospital-acquired infections and community acquired infections caused by Klebsiella pneumoniae.
Vaccine against hospital-acquired infections and community acquired infections caused by Pseudomonas aeruginosa
Vaccine against untreatable or difficult-to-treat infections, both hospital-acquired infections and community acquired infections, caused by Acinetobacter baumannii
VibioSphen is a SME healthcare biotechnology in infectious diseases founded in 2014. It focuses its activities on the challenge of antibiotic resistance and nosocomial infections. Its Research & Innovation (R&I) develops new immune modulator treatments complementary to antibiotics.To meet this goal VibioSphen has developed and proposes a scientific platform dedicated to study and validate new compounds and therapies. VibioSphen is an innovative company which provides services for pre-clinical assessments of new therapies on a broad catalogue of mouse experimental and in vitro predictive models from standard to custom-made models. His platform leads research permanently to improve the translational relevance to clinical cases and to provide new models
Vivexia is a french CRO company and offers a wide range of preclinical in-vivo models that enable the evaluation of anti-infective candidates (antibiotics, non antibiotics, phages, immunotherapies...) to prevent or treat life threatening infections arising from Gram-positive and Gram-negative bacteria.